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Methicillin (meticillin)-susceptible Staphylococcus aureus (MSSA) strains producing large amounts of type A
-lactamase (Bla) have been associated with cefazolin failures, but the frequency and impact of these strains
have not been well studied. Here we examined 98 MSSA clinical isolates and found that 26% produced type A
Bla, 15% type B, 46% type C, and none type D and that 13% lacked blaZ. The cefazolin MIC90 was 2 g/ml for
a standard inoculum and 32 g/ml for a high inoculum, with 19% of isolates displaying a pronounced inoculum
effect (MICs of >16 g/ml with 107 CFU/ml) (9 type A and 10 type C Bla producers). At the high inoculum,
type A producers displayed higher cefazolin MICs than type B or C producers, while type B and C producers
displayed higher cefamandole MICs. Among isolates from hemodialysis patients with MSSA bacteremia, three
from the six patients who experienced cefazolin failure showed a cefazolin inoculum effect, while none from the
six patients successfully treated with cefazolin showed an inoculum effect, suggesting an association between
these strains and cefazolin failure (P 0.09 by Fisher’s exact test). In summary, 19% of MSSA clinical isolates
showed a pronounced inoculum effect with cefazolin, a phenomenon that could explain the cases of cefazolin
failure previously reported for hemodialysis patients with MSSA bacteremia. These results suggest that for
serious MSSA infections, the presence of a significant inoculum effect with cefazolin could be associated with
clinical failure in patients treated with this cephalosporin, particularly when it is used at low doses.
Even though the rate of methicillin (meticillin) resistance in
Staphylococcus aureus is rising worldwide, a recent interna-
tional prospective study found that 85.2% of S. aureus strains
producing native valve endocarditis were susceptible to methi-
cillin (methicillin-susceptible S. aureus [MSSA]) (13). Cepha-
losporins (e.g., cefazolin) are recommended for patients with
MSSA endocarditis who have non-immediate-type hypersensi-
tivity to penicillin (1, 29), and in addition, patients are often
switched to cefazolin because of a more favorable dosing
schedule.
Approximately 90% of S. aureus isolates produce -lactama-
se(s) (Bla) (17). To date, four variants of Bla have been iden-
tified (A, B, C, and D) (10, 11, 16, 26), and each of these has
a different substrate profile (25). Type A Bla efficiently hydro-
lyzes cefazolin (30). Strains that produce a large amount of this
enzyme have been associated with cefazolin failures in patients
suffering from high-inoculum staphylococcal disease (e.g., en-
docarditis) (3, 5, 14, 15). Unlike low-level Bla producers, high-
level producer strains typically show high cefazolin MICs when
a large inoculum is used (14, 15). In high-inoculum, deep-
seated infections, the Bla produced by these strains of S. aureus
might inactivate the susceptible -lactam (i.e., cefazolin) at a
rate high enough to overcome its antibacterial effect. There-
fore, the presence of these strains may have significant clinical
implications in infections where the bacterial burden is high,
such as endocarditis, osteomyelitis, septic arthritis, pneumonia,
and/or large abscesses that have not been drained.
The goals of this study were to determine the frequency of
an inoculum effect with cefazolin as a measure of high-level
production of Bla and to determine the type of Bla present
among clinical isolates of MSSA. The relationship between an
inoculum effect with cefazolin and failure in a subgroup of
patients with S. aureus bacteremia was also assessed.
(Some results from this study were presented at the 48th
Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy-Infectious Disease Society of America 46th
Annual Meeting, 2008.)
MATERIALS AND METHODS
Strains. Eighty-six MSSA strains were randomly selected from repositories of
isolates from patients evaluated for complicated skin/soft tissue infections
(cSSTI) (ATLAS phase III trials), hospital-acquired pneumonia (HAP)
(ATTAIN phase III trials), and endocarditis (ICE cohort) (13, 18, 21, 22). These
clinical studies were conducted over the last several years in multiple countries
around the world. S. aureus strain TX0117 (high-level producer of type A Bla)
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(14), S. aureus ATCC 29213 (known to produce small amounts of type A Bla)
(10), and S. aureus ATCC 25923 (Bla-negative strain) were used as controls.
Twenty-four strains from a prospective observational study of MSSA bactere-
mia in patients on hemodialysis were also analyzed (23); these isolates were
specifically selected to include equal numbers of patients receiving either van-
comycin or cefazolin considered to have achieved cure or failure (six strains from
each group). The 12 strains from patients who received vancomycin as their
primary therapy were added to the 86 strains mentioned above, leading to 98
MSSA strains for the main analysis of the study. Investigators performing the
laboratory experiments were blinded to any clinical data related to the strains.
Susceptibility tests. MICs were determined by a broth microdilution method
using cation-adjusted Mueller-Hinton II broth, per Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines (4), with the following exceptions. Cefazolin
MICs were determined using low (5  104 CFU/ml), standard (5  105
CFU/ml) (SI), intermediate (5  106 CFU/ml), and high (5  107 CFU/ml)
(HI) inocula and were read at 24 h. Inocula were estimated by optical density
measurements, with random determinations of CFU/ml to confirm the inoculum
concentrations. Our definition of a pronounced inoculum effect was an MIC of
16 g/ml with the HI, which is the breakpoint for cefazolin nonsusceptibility
with SI, based on the CLSI recommendations. The Bla-negative strains were also
confirmed to be nitrocefin disk test negative after oxacillin induction (4). Cefaz-
olin and cefamandole were obtained from Sigma Chemicals (St. Louis, MO).
Sequence analysis. All strains underwent genomic DNA extraction by the
hexadecyltrimethyl ammonium bromide method, as described previously (12,
28), except for the addition of 10 units/ml of lysostaphin. PCRs were performed
using the following primers designed to amplify a 355-bp region within the
structural blaZ gene: F, 5-CAAAGATGATATAGTTGCTTATTC-3; and R,
5-CATATGTTATTGCTTGCACCAC-3. The size of PCR amplification prod-
ucts was verified by gel electrophoresis for the majority of the strains. PCR
products were then analyzed by DNA sequencing. Sequence analysis was per-
formed using the BLAST network service of the NCBI and DNASTAR software
(DNASTAR Inc.) to compare similarities among other sequences. The classifi-
cation of the Bla type of each strain was based on the amino acids at residues 128
and 216 encoded by the blaZ gene. For Bla type A, threonine is found at position
128 and serine is at position 216; for type B, lysine is at position 128 and
asparagine is at position 216; for type C, threonine is at position 128 and
asparagine is at position 216; and for type D, alanine is at position 128 and serine
is at position 216 (26). Control strains were S. aureus ATCC 29213, ATCC 25923,
and TX0117. Strains negative by PCR were also tested by high-stringency colony
lysate hybridization using our previously described method (20), with the minor
modification of using 40 units/ml of lysostaphin (Sigma, St. Louis, MO) in the
lysis solution. The PCR-amplified intragenic blaZ fragment from TX0117 (type
A) was used as a DNA probe for hybridization.
Statistical analyses. Comparisons between geometric mean (GM) MICs were
performed by the nonparametric Mann-Whitney U test. Analysis of the distri-
bution of the various types of Bla-producing strains was done by Fisher’s exact
test. P values of 0.05 were considered statistically significant. All statistical
comparisons were performed using the NCSS/PASS Dawson edition program
(Kaysville). In order to avoid selection bias, MSSA strains treated with cefazolin
in the bacteremia study were not included for the analysis of prevalence. This
study was reviewed and approved by the Duke University Institutional Review
Board.
RESULTS
Bla typing and cefazolin and cefamandole MICs. Among the
98 isolates, sequence analysis of a 355-bp region within the
blaZ gene containing residues 128 and 216 showed that 25.5%
of strains encoded type A Bla, 15.3% type B, 45.9% type C,
and none type D and that 13.2% were blaZ negative (con-
firmed by hybridization). Similar rates were seen for the dif-
ferent groups of strains included (strains from patients with
cSSTI, HAP, and endocarditis), except among MSSA blood-
stream isolates from hemodialysis patients, where type A
strains were slightly more common than type C strains.
In the initial analysis of 98 isolates from patients with endo-
carditis (n  29), HAP (n  29), cSSTI (n  28), and bacte-
remia (n  12), the cefamandole and cefazolin MIC50s and
MIC90s increased two- to fourfold for SI versus HI MICs
(Table 1). At HI, type A producers had higher cefazolin MICs
than cefamandole MICs, while type C strains displayed the
opposite effect. The type B Bla producers were similar to type
C Bla producers, but with a higher cefamandole MIC90 and a
lower cefazolin MIC90. Cefazolin GM MICs were significantly
higher among type A strains than among type C and type B
strains, while no significant difference was observed between
type B and C strains. No effect on the cefazolin and cefaman-
dole MICs at HI was seen among Bla-negative strains. The
control strains ATCC 29213 (weak Bla producer) and TX0117
(high-level type A Bla producer) (14) were both confirmed to
be type A producers; a PCR product was not amplified from
the ATCC 25923 strain (Bla negative). The Bla-negative
strains were also confirmed to be nitrocefin disk test negative
after oxacillin induction (4). As previously reported (14), no
increases in the cefazolin MIC at HI were observed with the
Bla-negative strain ATCC 25923, while a slight increase (to 4
g/ml) was seen with the weak type A Bla producer ATCC
29213.
Further analysis of the inoculum effect with cefazolin. We
next looked further at the interaction between cefazolin and
the 98 MSSA isolates, using four different inocula. When a low
inoculum was tested, all isolates were inhibited at 1 g/ml,
and with SI, all had an MIC of 4 g/ml (Table 2). With
increasing inoculum concentrations, the percentage of strains
inhibited at each concentration was reduced. The cefazolin
GM MIC for each inoculum was consistent with this observa-
tion, with a result of 0.5, 1, 2, and 5 g/ml with low, standard,
intermediate, and high inocula, respectively.
As shown in Table 2 for the HI, 19 of 98 MSSA strains
(19.2%) showed a pronounced inoculum effect with a cefazolin
MIC of 16 g/ml (the CLSI breakpoint for nonsusceptibility
using the standard inoculum), with two strains still growing at
64 g/ml. Sequencing analysis of these 19 isolates (from pa-
tients with bacteremia [n  3], endocarditis [n  2], HAP [n 
TABLE 1. Cefazolin and cefamandole MIC50s, MIC90s, and GM
MICs at HI and SI by type of Bla produceda
Strain group (n) Parameter
Cefazolin
MIC (g/ml)
Cefamandole
MIC
(g/ml)
SI HI SI HI
Type A Bla producers (25) GM MIC 1.3 11.2b 1 5.7
MIC50 1 8 1 4
MIC90 4 64 2 32
Type B Bla producers (15) GM MIC 0.9 2.8b 1.3 13.6
MIC50 1 2 1 8
MIC90 1 8 4 64
Type C Bla producers (45) GM MIC 0.9 5.6b 1.7 12.7
MIC50 1 4 2 16
MIC90 1 16 4 32
Bla-negative strains (13) GM MIC 0.6 1b 0.6 0.4
MIC50 1 1 1 1
MIC90 1 1 1 1
All strains (98) GM MIC 1 4.8 1.2 6.7
MIC50 1 4 1 8
MIC90 2 32 4 32
a HI, 5  107 CFU/ml; SI, 5  105 CFU/ml.
b The following P values were determined by the Mann-Whitney U test: for
type A versus type B producers, 0.002; for type A versus type C producers, 0.04;
for type B versus type C producers, 0.17; and for type A, B, and C producers
versus Bla-negative strains, 0.0001 for all.
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8], and cSSTI [n  6]) showed that 9 had type A blaZ and 10
had type C blaZ, while none had the type B blaZ gene. There-
fore, approximately 9% of all strains and 36% of type A strains
were hyperproducers of Bla type A. Analysis of these 19 strains
showed that the HI GM MIC of cefazolin was significantly
higher for the Bla type A strains than for the Bla type C strains
(Table 3).
Cefazolin inoculum effect with S. aureus bacteremia strains
from hemodialysis patients. Among the 24 strains isolated
from patients with MSSA bacteremia who were undergoing
hemodialysis, 9 were Bla type A, 3 type B, and 7 type C and 5
were Bla negative. Six (29%) of these 24 strains showed an
inoculum effect with cefazolin (MICs of 16 to 32 g/ml). Of
these six strains, five produced type A Bla (all with cefazolin
MICs of 32 g/ml), and one was a type C Bla producer. Two of
these strains were isolated from the six patients successfully
treated with vancomycin, one was from the six patients who
had failure with vancomycin, and three were from the six pa-
tients who failed cefazolin treatment. None of the strains show-
ing an inoculum effect with cefazolin were isolated from pa-
tients successfully treated with cefazolin (Table 4). The three
strains obtained from patients failing therapy with cefazolin
(two relapses and one death as preestablished causes of cefaz-
olin failure in the bacteremia study [23]) carried the type A Bla
gene and had a cefazolin MIC of 32 g/ml at HI. The cefazolin
GM MIC for the six strains belonging to the cefazolin failure
group was higher than the GM MIC for the six strains from the
cefazolin success group, although the difference was not sta-
tistically significant (8.9 g/ml versus 2.2 g/ml; P  0.138).
DISCUSSION
Cefazolin has been associated with clinical failures in pa-
tients with endocarditis (3, 5, 14, 15) caused by MSSA strains
displaying increased cefazolin MICs at HI (14, 15). However,
the frequency of these strains and the relationship between
them and clinical outcomes have not been clearly established.
Therefore, we determined the frequency of such strains among
clinical MSSA isolates, exploring also their presumptive role as
a cause of failure in patients with S. aureus bacteremia. As a
result, several key findings from the current study should be
underscored.
First, although the majority of clinical MSSA strains carry
Bla, there is significant variability between prevalence rates for
each type of this enzyme in published studies. Among clinical
MSSA strains studied in the present report, we found that type
C blaZ predominated (46%), followed by type A, type B, and
no blaZ gene. Importantly, the strains analyzed in this study
were from diverse populations enrolled in contemporary clin-
ical studies conducted worldwide, and some of them may have
been recovered from patients on prior antibiotics, possibly
affecting the type of strains isolated (8, 9); however, this fact
reflects what is seen in clinical practice. Different frequencies
of each type of staphylococcal Bla have been reported. Ker-
nodle et al., using the whole-cell extract method, reported that
54%, 15%, 30%, and 1% of strains were type A-, B-, C-, and
D-producing strains, respectively (10). More in agreement with
our findings, higher rates of type B/C strains (74%) than type
A strains (20%) have been reported in Japan (24). Unfortu-
nately, both of these comparator studies were conducted in the
1990s, making comparisons to current isolates of uncertain
significance.
Second, a pronounced inoculum effect against cefazolin was
present in approximately one-fifth of the clinical MSSA strains.
We found that 19 isolates (19.2%) showed a pronounced rise
in the cefazolin MIC, to 16 g/ml, with HI; 9 were Bla type
A and 10 were Bla type C producers. This rise in cefazolin MIC
may be a significant factor in serious MSSA infections and
could be the underlying cause of reported cases of cefazolin
failure in treatment of MSSA strains (3, 5, 14, 15). It should be
noted, however, that only 9 of 25 (36%) type A and 10 of 45
(24%) type C Bla producer strains displayed a significant ce-
fazolin inoculum effect. This highlights the fact that it is not
only the type of Bla that determines the cefazolin inoculum
effect but also the amount of Bla produced. None of the type
B Bla-producing strains showed a significant inoculum effect
on the cefazolin MIC, and as expected, no inoculum effect was
observed among Bla-negative isolates. As a screening proce-
dure, a semiquantitative nitrocefin disk reaction using a con-
TABLE 2. Correlation between cefazolin MIC and inoculum
size for 98 strains
Inoculum size
% of strains inhibited at cefazolin concn (g/ml)
1 2 4 8 16a 32 64 128
Low 100 0 0 0 0 0 0 0
Standard 89 5 6 0 0 0 0 0
Intermediate 33 50 8 2 2 1 3 0
High 23 12 20 24 5 9 3 2
a CLSI breakpoint for nonsusceptibility.
TABLE 3. Analysis of strains with cefazolin MICs of 16 g/ml
(n  19) at HI
Strain group
Cefazolin GM MIC
(range) (g/ml)
Cefamandole GM MIC
(range) (g/ml)
SI HI SI HI
Bla A-producing
strains (n  9)
2.3 (1–4) 54.9a (32 –128) 1.7 (0.5–2) 13.7b (8–32)
Bla C-producing
strains (n  10)
1.1 (0.5–2) 22.7a (16–32) 2.3 (1–8) 34.3b (32–64)
a P value  0.002 by Mann-Whitney U test.
b P value  0.01 by Mann-Whitney U test.
TABLE 4. Cefazolin MICs at HI and distribution of strains with a
cefazolin inoculum effect in MSSA bacteremia substudy
Treatment arm (n)
No. of strains
with pronounced
inoculum effecta
Cefazolin GM
MIC at HI
(g/ml)
Vancomycin (12)
Cure (6) 2 5
Failure (6) 1 4
Cefazolin (12)
Cure (6) 0b 2.2c
Failure (6) 3b 8.9c
a Cefazolin MIC of 16 g/ml (five type A and one type C Bla producers).
b P value 0.090 (cefazolin failure versus cefazolin cure) by Fisher’s exact test.
c P value  0.138 (cefazolin GM MIC for cefazolin failure group versus that
for cefazolin cure group) by Mann-Whitney U test.
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centration of cells from an overnight culture could identify
most type A Bla-producing strains with a significant cefazolin
inoculum effect but failed to detect type C ones (our personal
observations).
Third, the presence of MSSA bloodstream isolates produc-
ing Bla type A with a pronounced inoculum effect may be
associated with failures of cefazolin. Overall, we found three
strains with high-level production of Bla A (cefazolin MIC of
32 g/ml at HI) among the six subjects who failed cefazolin
therapy, while none of the six MSSA strains isolated from the
six patients successfully treated with cefazolin showed a cefa-
zolin inoculum effect. While these findings did not reach sta-
tistical significance, they show a suggestive trend. Moreover, a
numerically higher cefazolin GM MIC was found for the
cefazolin failure group than for the cefazolin success group.
These results suggest a possible role of high-level production
of type A Bla as a cause of cefazolin failure. Interestingly, a
recent retrospective study reported favorable outcomes for 12
patients with prosthetic joint infection caused by type A Bla-
producing MSSA strains who were treated with cefazolin plus
an antibiotic-impregnated spacer (19). However, it was not
determined if these strains were high-level producers of type A
Bla, which is likely the critical factor. Furthermore, these pa-
tients had an appropriate surgical procedure, which would
decrease the number of remaining bacteria.
Deep-seated staphylococcal infections are difficult to treat,
frequently requiring surgical intervention. The number of or-
ganisms inside an infected vegetation may be as high as 1011
CFU/g of tissue (6). Considering that up to one-half of the Bla
can be excreted (2), the concentration of enzyme inside vege-
tations might be substantial. If the infecting MSSA strain pro-
duces large amounts of an active Bla, the enzyme may inacti-
vate its target at a rate high enough to overcome its
antibacterial effect. In the case of cefazolin, serum concentra-
tions are still17 g/ml 4 h after 1 g is given intravenously (7).
However, concentrations inside infected tissue are consider-
ably lower (e.g., 6.9 g/ml at 60 min in bone [27]), and con-
centrations within a vegetation or a deep-seated abscess are
also likely to be lower than those in serum. As with other
-lactams, the time that the cephalosporin concentration is
maintained above the MIC is critical for bacterial suppression.
However, if a strain produces sufficient amounts of Bla with a
high hydrolysis rate against the cephalosporin, then the MIC
inside the HI-infected site might be increased significantly,
leading to a reduction in the time that the cephalosporin con-
centration is above the MIC. It is likely that increasing the
antibiotic concentration at the infection site, up to a point,
could overcome the Bla effect.
In conclusion, a pronounced inoculum effect against cefazo-
lin, with elevation of the MIC to 16 g/ml, was seen with
almost 20% of strains studied, with about half of them being
type A Bla producers. Our findings also suggest an association
between the presence of a cefazolin inoculum effect and cefaz-
olin failure in patients with MSSA bacteremia, consistent with
previous reports (3, 5, 14, 15). Therefore, in serious and HI
infections caused by MSSA, particularly those which have not
undergone debridement and/or device removal, the presence
of an inoculum effect with cefazolin could be associated with
clinical failure, especially if cefazolin is administered at low
doses.
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